Topic summary

State-level differences that actually matter

Regional › North America compounding telehealth insurance FDA Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 11, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

g.valckenaereTL3Regular5 May 2025 · edited#4

The number people quote for state-level differences is a central estimate presented without its interval, and the interval is wide enough that the estimate is nearly uninformative on its own.

27 likes 15mo

g.ekstromTL2 Solution30 May 2025#5

Before the thread moves on from state-level differences — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.

9 likes 14mo

n.serranoTL214 Jul 2025#7

s.roos, post #3: Building on post #2 rather than restating it. Cost comparisons should state whether they include the device and the dispensing fee, because those differ between routes and between states. Go to post

Taking post #6 at face value and following it one step further.

The public assessment documents published at approval are free, detailed and largely unread here.

I am describing what is, rather than arguing for what should be.

19 likes in reply to #3 12mo

ni.stanescuTL225 Aug 2025#9

Adding the measurement that post #6 says would settle it.

One caution on state-level differences: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.

14 likes in reply to #3 11mo

ambient_reviewTL3Regular14 Sep 2025#10

BBramley, post #6: Prior authorisation criteria are usually published by the payer and reading them before the appointment changes the outcome more than anything else does. This is where my knowledge stops and I would rather mark the edge than blur it. Go to post

Post #9 describes the usual case. This is about the unusual one.

Pharmacy practice varies between pharmacies within the same city, so two honest accounts can be entirely different.

28 likes in reply to #6 10mo

Read the full topic (11 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
About the North America category Regional › North America FDA compounding insurance Pinned Wiki US and Canadian regulation, compounding, and coverage. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a note. If the scope…	+3	7	43k	9mo
Coverage in the US: a map of the usual obstacles Regional › North America FDA insurance telehealth compounding Coverage in the US: a map of the usual obstacles — setting out what I have, and where I think it stops being reliable. Trying to establish the boundary conditions on coverage. The general claim is fine; I…	+46	50	7.9k	5mo
[2026 update] US compounding rules and how they changed Regional › North America FDA compounding insurance Solved US compounding rules and how they changed Writing it up because I had to work it out twice and would rather nobody else did. Regional question, dated January 2026, because everything in this category expires.…	+32	37	7.4k	10mo
Canadian access and provincial variation — one year on Regional › North America FDA compounding insurance Canadian access and provincial variation — one year on Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about Canadian access and provincial variation…	+43	47	964	12mo
US compounding rules and how they changed Regional › North America FDA telehealth insurance Closed US compounding rules and how they changed — setting out what I have, and where I think it stops being reliable. Reporting a regional experience with the date and the jurisdiction attached, because an undated…	+62	68	1.4k	20mo

Related topics — sharing the tags compounding, telehealth, insurance

Topic	Participants	Replies	Views	Activity
[2026 update] Availability by country, dated, with primary sources Access › International MHRA NHS telehealth personal import On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…	+40	45	14k	4mo
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Sourcing › Regulatory FDA EMA compounding research use only Closed On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. I would like to know what people here actually do…	+76	82	52k	11mo
[2026 update] Travelling with an injectable: documentation and practicalities Access › International telehealth EMA MHRA NHS Travelling with an injectable: documentation and practicalities Writing it up because I had to work it out twice and would rather nobody else did. Dated regional question, February 2026, because everything in…	+107	111	12k	1d
Second pass at: Manufacturer assistance programmes and their eligibility rules Access › Pricing cost per milligram data table compounding formulary Second pass at: Manufacturer assistance programmes and their eligibility rules — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…	+13	17	1.8k	16mo
Follow-up: State-level differences that actually matter Regional › North America FDA telehealth insurance State-level differences that actually matter — setting out what I have, and where I think it stops being reliable. A follow-up question about State-level differences that I did not know to ask the first time.…	+90	96	4.1k	4mo